920 related articles for article (PubMed ID: 36951829)
1. Association of Treatment With Nirmatrelvir and the Risk of Post-COVID-19 Condition.
Xie Y; Choi T; Al-Aly Z
JAMA Intern Med; 2023 Jun; 183(6):554-564. PubMed ID: 36951829
[TBL] [Abstract][Full Text] [Related]
2. Molnupiravir and risk of post-acute sequelae of covid-19: cohort study.
Xie Y; Choi T; Al-Aly Z
BMJ; 2023 Apr; 381():e074572. PubMed ID: 37161995
[TBL] [Abstract][Full Text] [Related]
3. Nirmatrelvir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records.
Xie Y; Bowe B; Al-Aly Z
BMJ; 2023 Apr; 381():e073312. PubMed ID: 37041016
[TBL] [Abstract][Full Text] [Related]
4. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ
JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790
[TBL] [Abstract][Full Text] [Related]
5. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015395. PubMed ID: 36126225
[TBL] [Abstract][Full Text] [Related]
6. Nirmatrelvir or Molnupiravir Use and Severe Outcomes From Omicron Infections.
Lin DY; Abi Fadel F; Huang S; Milinovich AT; Sacha GL; Bartley P; Duggal A; Wang X
JAMA Netw Open; 2023 Sep; 6(9):e2335077. PubMed ID: 37733342
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system.
Lewnard JA; McLaughlin JM; Malden D; Hong V; Puzniak L; Ackerson BK; Lewin BJ; Kim JS; Shaw SF; Takhar H; Jodar L; Tartof SY
Lancet Infect Dis; 2023 Jul; 23(7):806-815. PubMed ID: 36933565
[TBL] [Abstract][Full Text] [Related]
8. Factors Associated With Severe COVID-19 Among Vaccinated Adults Treated in US Veterans Affairs Hospitals.
Vo AD; La J; Wu JT; Strymish JM; Ronan M; Brophy M; Do NV; Branch-Elliman W; Fillmore NR; Monach PA
JAMA Netw Open; 2022 Oct; 5(10):e2240037. PubMed ID: 36264571
[TBL] [Abstract][Full Text] [Related]
9. Association of nirmatrelvir for acute SARS-CoV-2 infection with subsequent Long COVID symptoms in an observational cohort study.
Durstenfeld MS; Peluso MJ; Lin F; Peyser ND; Isasi C; Carton TW; Henrich TJ; Deeks SG; Olgin JE; Pletcher MJ; Beatty AL; Marcus GM; Hsue PY
J Med Virol; 2024 Jan; 96(1):e29333. PubMed ID: 38175151
[TBL] [Abstract][Full Text] [Related]
10. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.
Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
Lancet; 2022 Oct; 400(10359):1213-1222. PubMed ID: 36216007
[TBL] [Abstract][Full Text] [Related]
11. Persistent COVID-19 Symptoms at 6 Months After Onset and the Role of Vaccination Before or After SARS-CoV-2 Infection.
Richard SA; Pollett SD; Fries AC; Berjohn CM; Maves RC; Lalani T; Smith AG; Mody RM; Ganesan A; Colombo RE; Lindholm DA; Morris MJ; Huprikar N; Colombo CJ; Madar C; Jones M; Larson DT; Bazan SE; Mende K; Saunders D; Livezey J; Lanteri CA; Scher AI; Byrne C; Rusiecki J; Ewers E; Epsi NJ; Rozman JS; English C; Simons MP; Tribble DR; Agan BK; Burgess TH;
JAMA Netw Open; 2023 Jan; 6(1):e2251360. PubMed ID: 36652247
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of COVID-19 Treatment With Nirmatrelvir-Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes.
Bajema KL; Berry K; Streja E; Rajeevan N; Li Y; Mutalik P; Yan L; Cunningham F; Hynes DM; Rowneki M; Bohnert A; Boyko EJ; Iwashyna TJ; Maciejewski ML; Osborne TF; Viglianti EM; Aslan M; Huang GD; Ioannou GN
Ann Intern Med; 2023 Jun; 176(6):807-816. PubMed ID: 37276589
[TBL] [Abstract][Full Text] [Related]
13. Association of COVID-19 Vaccination With SARS-CoV-2 Infection in Patients With Cancer: A US Nationwide Veterans Affairs Study.
Wu JT; La J; Branch-Elliman W; Huhmann LB; Han SS; Parmigiani G; Tuck DP; Brophy MT; Do NV; Lin AY; Munshi NC; Fillmore NR
JAMA Oncol; 2022 Feb; 8(2):281-286. PubMed ID: 34854921
[TBL] [Abstract][Full Text] [Related]
14. Risks and burdens of incident dyslipidaemia in long COVID: a cohort study.
Xu E; Xie Y; Al-Aly Z
Lancet Diabetes Endocrinol; 2023 Feb; 11(2):120-128. PubMed ID: 36623520
[TBL] [Abstract][Full Text] [Related]
15. One-Year Adverse Outcomes Among US Adults With Post-COVID-19 Condition vs Those Without COVID-19 in a Large Commercial Insurance Database.
DeVries A; Shambhu S; Sloop S; Overhage JM
JAMA Health Forum; 2023 Mar; 4(3):e230010. PubMed ID: 36867420
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of Nirmatrelvir-Ritonavir Against the Development of Post-COVID-19 Conditions Among U.S. Veterans : A Target Trial Emulation.
Ioannou GN; Berry K; Rajeevan N; Li Y; Mutalik P; Yan L; Bui D; Cunningham F; Hynes DM; Rowneki M; Bohnert A; Boyko EJ; Iwashyna TJ; Maciejewski ML; Osborne TF; Viglianti EM; Aslan M; Huang GD; Bajema KL
Ann Intern Med; 2023 Nov; 176(11):1486-1497. PubMed ID: 37903369
[TBL] [Abstract][Full Text] [Related]
17. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.
Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
Lancet Infect Dis; 2022 Dec; 22(12):1681-1693. PubMed ID: 36029795
[TBL] [Abstract][Full Text] [Related]
18. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study.
Aggarwal NR; Molina KC; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Peers JL; Russell S; Wynia MK; Ginde AA
Lancet Infect Dis; 2023 Jun; 23(6):696-705. PubMed ID: 36780912
[TBL] [Abstract][Full Text] [Related]
19. Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System : A Population-Based Cohort Study.
Dryden-Peterson S; Kim A; Kim AY; Caniglia EC; Lennes IT; Patel R; Gainer L; Dutton L; Donahue E; Gandhi RT; Baden LR; Woolley AE
Ann Intern Med; 2023 Jan; 176(1):77-84. PubMed ID: 36508742
[TBL] [Abstract][Full Text] [Related]
20. Multidimensional Sleep Health Prior to SARS-CoV-2 Infection and Risk of Post-COVID-19 Condition.
Wang S; Huang T; Weisskopf MG; Kang JH; Chavarro JE; Roberts AL
JAMA Netw Open; 2023 May; 6(5):e2315885. PubMed ID: 37252741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
